WAPPS-Hemo continues to provide extraordinary value-added services with the addition of a new “Switching Tool”.
This tool specifically predicts outcomes when switching a factor VIII patient from Kovaltry, an unmodified, full-length, standard-half-life recombinant factor VIII (FVIII) concentrate to Jivi, a conjugated 60-kDa branched polyethylene glycol (PEG) extended half-life molecule.